久久一区二区三区四区_欧美高清dvd_日韩欧美在线看_国产精品欧美一区二区_av天天看_欧美精品免费观看二区

Clearbridge BioMedics  
Clearbridge Biomedics 專精應用于腫瘤科學研究與診斷的創新平臺開發。
Clearbridge Biomedics 是新加坡國立大學衍生公司，運用研究伙伴的創新技術，致力于革命性的癌癥診斷與病患照護相關醫療器材開發。
ClearCell 系統由專利申請中的CTChip 組成，可以有效的從小量病患血液檢體偵測并分離完整的循環腫瘤細胞。分離出的循環腫瘤細胞可直接在CTChip 染色進行鑒定與計數，或是取
出進行更進一步的分子分析。 ClearCell 系統的目標是成為癌癥檢驗、分期以及監控提供新世代非侵入性液態切片的革命性平臺。
Clearbridge Biomedics 的總部位于新加坡，客戶遍布亞洲、歐洲與北美洲。

Clearbridge BioMedics (CBB) is a spin-off from National University of Singapore (NUS) and is also the first incubatee of Clearbridge Accelerator, a Singapore Government (National Research Foundation) backed high-technology incubator. CBB is also a successful recipient of SPRING Singapore’s Technology Enterprise Commercialisation Scheme (TECS) Proof-of-Value (POV) Grant.

Leveraging on a patent-pending microfluidic biochip invention, our ClearCell? System, comprising the ClearCell? Unit and a range of CTChips?, are able to effectively detect and isolate wholly intact Circulating Tumour Cells (CTCs) from patients' blood samples. CTCs are extremely rare cancer cells that have detached from a primary tumour and are circulating in the bloodstream. Capturing and counting CTCs could enable clinicians to conduct cancer screening, diagnosis and post-cancer monitoring that will be invaluable in allowing clinicians to make timely and life-saving decisions. Most impressively, the ClearCell? System is able to capture and retrieve these CTCs, allowing researchers to conduct critical genetic analysis to optimise cancer therapies, paving the way for personalised cancer treatment.

The ClearCell? System aims to be the next generation of non-invasive “liquid biopsy” approach for cancer screening, diagnosis, staging, personalised medicine, and treatment monitoring.

Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North America.

Our Mission

Clearbridge BioMedics’ mission is to innovate and develop novel medical research tools and diagnostic products using cutting-edge technologies, in order to catalyse medical research and discovery, revolutionise disease management, and advance patient care.